title: Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study.
abstract: Ro52 antigen has recently been identified as TRIM21 protein, but the clinical significance of anti-Ro52/TRIM21 antibodies remains controversial. The aim of this multicentric study was to investigate the significance of anti-Ro52 antibodies without anti-SSA/Ro60 antibodies in various connective diseases. Sera were selected by each laboratory using its own method (ELISA, immunodot or Luminex technology), and then performed with ANA Screen BioPlex™ reagent (BIO-RAD). Among the 247 screened sera, 155/247 (63%) were confirmed as anti-Ro52 positive and anti-SSA/Ro60 negative. These sera were analyzed for the detection of other antibodies in relation with clinical settings. Isolated anti-Ro52 antibodies were detected in 89/155 (57%) sera. For the remaining sera (66/155), the main antibodies associations were Sm/SmRNP or Chromatin (n=38; 57%), Jo1 (n=17; 26%) and CenpB (n=9; 14%). Clinical data from the 155 patients showed high prevalence in autoimmune diseases (73%) including myositis or dermatomyositis (n=30), lupus (n=23); Sjögren and/or sicca syndrome (n=27); CREST or Systemic sclerosis (n=11) and autoimmune hepatitis (n=11). We found that pulmonary manifestations were often associated with the presence of anti-Ro52 antibodies (n=34, 22%), in addition with anti-tRNA synthetases, anti-SRP or anti-Ku antibodies (18/34) or isolated in half of cases (16/34). Separate detection of anti-Ro52 antibodies might be useful in related antisynthetase syndrome diagnosis. The presence of anti-Ro52 antibodies should probably precede development of autoimmune disease and must induce sequential follow-up of positive patients, particularly in interstitial lung disease progression.
authors: Laboratoire d'Immunochimie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. pascale.ghillani-dalbin@psl.aphp.fr
authors: P
authors: P
authors: Ghillani
authors: C
authors: C
authors: André
authors: C
authors: C
authors: Toly
authors: A M
authors: AM
authors: Rouquette
authors: D
authors: D
authors: Bengoufa
authors: P
authors: P
authors: Nicaise
authors: C
authors: C
authors: Goulvestre
authors: A
authors: A
authors: Gleizes
authors: M A
authors: MA
authors: Dragon-Durey
authors: M A
authors: MA
authors: Alyanakian
authors: P
authors: P
authors: Chretien
authors: S
authors: S
authors: Chollet-Martin
authors: L
authors: L
authors: Musset
authors: B
authors: B
authors: Weill
authors: C
authors: C
authors: Johanet
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001327:Autoimmune Diseases / Q000097:blood* / Q000276:immunology; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012261:Ribonucleoproteins / Q000276:immunology; D055815:Young Adult; D000099207:SS-A Antigen
chemical_list: D000906:Antibodies; D001323:Autoantibodies; D012261:Ribonucleoproteins; D000099207:SS-A Antigen